Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, researchers found that ritlecitinib, a JAK3/TEC inhibitor, significantly improves hair regrowth, quality of life, and psychological well-being in patients with severe alopecia areata who had inadequate or no response to baricitinib, a JAK1/2 inhibitor.

This study evaluates the efficacy and safety of a higher dose (100-mg) of ritlecitinib for treating severe alopecia areata, comparing it to external and synthetic placebo control groups.

In this study, JAK inhibitors for treating alopecia areata and atopic dermatitis were generally well tolerated in a real-world setting, with most adverse events being mild or moderate and rare serious cases resembling the general population incidence.

This meeting summary discusses the ISHR's focus on hair restoration, featuring Julius Caesar's image, but reports no new research findings.

This study found an IFIS incidence rate of 3.18% among cataract surgeries in a Chinese hospital and identified reserpine, clozapine, and post-panretinal photocoagulation as new risk factors.

In this real-world study, 27% of alopecia areata patients treated with ritlecitinib achieved a target SALT score, a result consistent with clinical trial findings, highlighting the value of patient-reported outcomes in understanding treatment impact beyond traditional measures.

The literature review concluded that while 5α-reductase inhibitors hold promise for managing prostate cancer, they raise significant safety concerns regarding their association with high-grade tumors and mortality, highlighting the need for careful consideration in their clinical use.

This review reports that three JAK inhibitors—baricitinib, ritlecitinib, and deuruxolitinib—have gained FDA approval for treating alopecia areata due to their demonstrated efficacy in fostering hair regrowth in clinical trials.

This paper reports insights from an Expert Panel convened by the Society for Immunotherapy of Cancer on managing immune-related adverse events (irAEs) following immune checkpoint inhibitor therapy, highlighting surveillance gaps and the need for a comprehensive irAE registry to improve post-treatment care for cancer survivors.

This paper reviews existing and emerging therapies for alopecia areata, describing the impact of targeted treatments in this field, and introduces a global network of disease registers to study the long-term safety and effectiveness of these new options.

This study found that patients with rheumatoid arthritis, atopic dermatitis, and alopecia areata receiving baricitinib had low incidence rates of adverse events, especially among low-risk individuals, with varying rates among those at higher risk.

In this study, ritlecitinib, an oral JAK3/TEC inhibitor, was evaluated for safety in patients aged 12 and older with alopecia areata across four clinical trials up to 36 months, showing a safety profile with reported adverse events and lab abnormalities summarized per dosing groups.

This study observed that most patients with alopecia areata experienced sustained scalp hair regrowth after 48 weeks of ritlecitinib treatment, with safety consistent with prior findings.

This study found that IsoPSA's ability to detect both any prostate cancer and clinically actionable prostate cancer remains unaffected by medications like 5-ARIs and α-blockers, which are commonly used to treat benign prostatic hyperplasia symptoms.

This research investigated the design and synthesis of steroid-based compounds as aromatase inhibitors for breast cancer, finding that certain structural modifications significantly enhance their inhibitory potency.

This review analyzes the mechanism and evidence supporting the approved use of ritlecitinib, a JAK3/TEC kinase inhibitor, for treating severe alopecia areata in patients aged 12 and older, highlighting its role in the changing therapeutic landscape of this immune-mediated disease.

This source reported that patients who initially responded to ritlecitinib treatment showed sustained hair regrowth through week 48, with up to one-third of those not meeting target efficacy at week 24 also achieving a response with continued treatment.

This study demonstrated that AIRE-deficient rats exhibit key symptoms of APECED, making them a relevant model for exploring potential treatments.

This abstract mentions the XI International Congress of the ISHR in Bari but reports no new research findings.

This study found that JAK inhibitors used to treat alopecia areata have varied safety profiles, with different adverse events associated with each drug; tofacitinib and ruxolitinib had earlier onset of events, while baricitinib and ritlecitinib showed distinct delayed patterns.

Off-label drug use can be risky and requires careful consideration to ensure patient safety.

This study reports the first known occurrence of Leporacarus gibbus infestation alongside Cheyletiella parasitovorax and Psoropotes cuniculi in a domestic rabbit in Espírito Santo, Brazil.

In this Italian retrospective study, ritlecitinib 50 mg/day showed effectiveness and good tolerability for treating severe alopecia areata over 24 weeks, achieving significant hair regrowth particularly in adolescents, as well as improvements in eyebrows, eyelashes, nails, and quality of life, with mostly mild adverse effects.

In this retrospective study, baricitinib and ritlecitinib showed similar effectiveness and safety over 52 weeks for treating severe alopecia areata, with non-severe adverse events more common for baricitinib, driven by weight gain.

This study found that the oral JAK inhibitors ritlecitinib and brepocitinib were effective in maintaining hair regrowth in alopecia areata with continuous use, though efficacy decreased after withdrawal.

This historical review traces the discovery of 5-alpha reductase inhibitors, widely used in urology, from the study of guevedoces, Dominican children with a rare disorder leading to significant androgenization at puberty.

This study suggests that monitoring CD8+ TEMRA cells in patients with rapidly progressive alopecia areata treated with intravenous corticosteroids could help predict therapeutic outcomes.